Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Glut1 inhibitor BAY-876 and TNF treated LLC cells

ABSTRACT: Glut1 inhibitor BAY-876 and TNF treated LLC cells

PROVIDER: PRJNA888760 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21848054_1.fastq.gz	Fastqsanger.gz
	SRR21848054_2.fastq.gz	Fastqsanger.gz
	SRR21848055_1.fastq.gz	Fastqsanger.gz
	SRR21848055_2.fastq.gz	Fastqsanger.gz
	SRR21848056_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 56

Similar Datasets

Glut1 inhibitor BAY-876 and TNF treated LLC cells

Project description:To investigate the mechanisms by which Glut1 inactivation synergized with TNFa to induce cell death, LLC cells were either pretreated or left untreated for 200nM BAY-876 for 24 hours, followed by treatment with 20ng/ml TNF or left untreated for 32 hours.To compare the expression of glucose transporters in tumor and tumor-reactive immune T cells, we analyzed the expression levels ofperformed RNAseq on adoptively transferred adoptively transferred OT-I T cells and LLC-OVA cells, respectively.

2023-01-18 | GSE215107 | GEO

Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876.

Project description:Despite the long-known fact that the facilitative glucose transporter GLUT1 is one of the key players safeguarding the increase in glucose consumption of many tumor entities even under conditions of normal oxygen supply (known as the Warburg effect), only few endeavors have been undertaken to find a GLUT1-selective small-molecule inhibitor. Because other transporters of the GLUT1 family are involved in crucial processes, these transporters should not be addressed by such an inhibitor. A high-throughput screen against a library of ∼3 million compounds was performed to find a small molecule with this challenging potency and selectivity profile. The N-(1H-pyrazol-4-yl)quinoline-4-carboxamides were identified as an excellent starting point for further compound optimization. After extensive structure-activity relationship explorations, single-digit nanomolar inhibitors with a selectivity factor of >100 against GLUT2, GLUT3, and GLUT4 were obtained. The most promising compound, BAY-876 [N4 -[1-(4-cyanobenzyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide], showed good metabolic stability in vitro and high oral bioavailability in vivo.

| S-EPMC5095872 | biostudies-literature

Effect of sgRNA-mediated disruption of GLUT1 on gene expression on c-Kit+ MLL::AF9 leukemia cells

Project description:Acute myeloid leukemia (AML) is initiated and propagated by leukemia stem cells (LSCs), a self-renewing population of leukemia cells. Here we performed an in vivo CRISPR screen and identified the facilitated glucose transporter type 1 (GLUT1) as a critical metabolic dependency for murine MLL::AF9 LSCs. GLUT1 disruption by genetic ablation or by pharmacological inhibition with BAY-876 led to suppression of leukemia progression and improved survival in an MLL::AF9 mouse model of AML. Glut1 inhibition further resulted in glycolytic suppression, decreased levels of tricarboxylic cycle intermediates, and elevated levels of amino acids. These changes in metabolic profile coincided with increased autophagic activity and differentiation of AML cells. Notably, dual inhibition of GLUT1 and oxidative phosphorylation exhibited synergistic anti-leukemic effects in human AML cells. Collectively, these findings increase our understanding of how murine LSCs are metabolically regulated and highlight GLUT1 inhibition as a promising therapeutic adjuvant approach in AML.

2022-07-28 | GSE209636 | GEO

Gene expression profiling of mature dendritic cells from mice s. c. treated with GM-CSF-gene transduced LLC cells (LLC/SeV/GM) or control cells (LLC, LLC/SeV/GFP)

Project description:Irradiated granulocyte macrophage-colony stimulating factor (GM-CSF)-transduced autologous tumor cells induce substantial antitumor immunity through the maturation and migration of dendritic cells (DCs). However, little is known about the key molecules involved in GM-CSF-sensitized DCs (GM-DCs) in tumor draining lymph nodes (TDLNs). We initially confirmed that mice subcutaneously injected with poorly immunogenic syngeneic Lewis lung carcinoma (LLC) cells transduced with Sendai virus encoding GM-CSF (LLC/SeV/GM) significantly rejected the tumor growth. Using microarray expression profiling, we obtained a large number of gene expression data files from GM-DCs and control DCs in TDLNs, and subjected them to network-based cluster analysis and unexpectedly unraveled the expression levels of type I IFNs-related genes specifically expressed in plasmacytoid DCs (pDC) were robustly up-regulated in GM-DCs. In vivo depletion assay showed that pDC-depleted mice treated with subcutaneous LLC/SeV/GM cells abrogated the antitumor effects observed in control mice. Moreover combination use of imiquimod for TLR7 triggering on pDC with irradiated LLC/SeV/GM cells induced a significant therapeutic antitumor effect with marked induction of CD9+ pDC with antitumor phenotype, whereas other control mice groups had only minimal to-modest antitumor responses, implicating that this combined vaccine strategy using imiquimod could be promising for improvement of GM-CSF-induced antitumor immunity. Mouse GM-CSF induced gene expression in mature dendritic cells in tumor draining lymph nodes from C57/BL6N female mouse was measured at 2 days after s.c. tumor challenge with GM-CSF gene-transduced LLC cells (LLC/SeV/GM) or control cells (LLC, LLC/SeV/GFP).

2013-09-30 | E-GEOD-43169 | biostudies-arrayexpress

miR-876 is a tumor suppressor on 9p21 that is inactivated in melanoma and targets ERK

Project description:While melanomas commonly harbor losses of 9p21, on which CDKN2A resides, the presence of additional tumor suppressor elements at this locus is incompletely characterized. Here we assess the expression levels and functional role of microRNA-876 (miR-876), whose gene also maps to 9p21.

2024-08-21 | GSE267789 | GEO

Stop Mole LLC

Project description:Stop Mole LLC

| PRJNA1097484 | ENA

Transcription profiling of Mus musculus PBS vs IL-5 trerated LLC cells, and LLC vs B16 cells at baseline conditions

Project description:PBS and Il-5 (22 pM) treated LLC and B16 cells were harvested after 24 hours, for comparison between: 1) PBS and IL-5 trerated LLC cells, and 2) btween LLC and B16 cells at baseline conditions.

2010-12-13 | E-MEXP-2490 | biostudies-arrayexpress

Murine cells: MSC+LLC-serum-exosome vs LLC-serum-exosome

Project description:Murine cells: MSC+LLC-serum-exosome vs LLC-serum-exosome

| PRJNA490558 | ENA

Clostridiales bacterium oral taxon 876

Project description:Clostridiales bacterium oral taxon 876 overview

| PRJNA240618 | ENA

Murine cells: MSC+LLC-serum-exosome vs LLC-serum-exosome

Project description:Exosomal miRNAs including 86 exosomal miRNAs were significantly increased and 354 exosomal miRNAs were significantly decreased in the co-injection group compared to LLC injection alone through expression profiling of a total of 1903 genes.

2019-04-02 | GSE119887 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data